News and Trends 23 Nov 2022
First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease
A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients has been given to the first subjects in a trial run by Infex Therapeutics….